{
    "root": "580955ba-86f6-4e86-b0fa-dd44e8828b0e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pregabalin",
    "value": "20250301",
    "ingredients": [
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        }
    ],
    "indications": "pregabalin capsule indicated : • management neuropathic pain associated diabetic peripheral neuropathy • management postherpetic neuralgia • adjunctive therapy treatment partial onset seizures patients 17 years age older • management fibromyalgia • management neuropathic pain associated spinal cord injury pediatric information approved pfizer 's lyrica ( pregabalin ) capsules oral solution products . however , due pfizer 's marketing exclusivity rights , product labeled pediatric information .",
    "contraindications": "• adult , begin dosing 150 mg/day . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) • dosing recommendations : indication dosing regimen maximum dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day adjunctive therapy partial-onset seizures adult patients 17 years age older ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day • • dose adjusted adult patients reduced renal function . ( 2.7 )",
    "warningsAndPrecautions": "75 mg capsules white white color granular powder filled size `` 4 `` hard gelatin capsules white opaque body imprinted `` pgbn `` light blue opaque cap imprinted `` 75 `` black ink available : storage handling store 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) ( usp controlled room temperature ) .",
    "adverseReactions": "pregabalin contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.2 ) ] .",
    "indications_original": "Pregabalin capsule is indicated for:\n                  \n                     \n                        •\n                        \n                           Management of neuropathic pain associated with diabetic peripheral neuropathy\n                        \n                     \n                     \n                        •\n                        Management of postherpetic neuralgia\n                     \n                     \n                        •\n                        Adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older\n                     \n                     \n                        •\n                         Management of fibromyalgia\n                     \n                     \n                        •\n                        Management of neuropathic pain associated with spinal cord injury\n                     \n                  \n                  \n                     Pediatric use information is approved for Pfizer's LYRICA (pregabalin) Capsules and Oral  Solution products. However, due to Pfizer's marketing exclusivity rights, this drug product  is not labeled with that pediatric information.",
    "contraindications_original": "• For adult indications, begin dosing at 150 mg/day. (2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) • Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain (2.2) 3 divided doses per day 300 mg/day within 1 week PHN (2.3) 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day Adjunctive Therapy for Partial-Onset Seizures in Adult Patients 17 Years of Age and Older (2.4) 2 or 3 divided doses per day Maximum dose of 600 mg/day Fibromyalgia (2.5) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day Neuropathic Pain Associated with Spinal Cord Injury (2.6) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day • • Dose should be adjusted in adult patients with reduced renal function. (2.7)",
    "warningsAndPrecautions_original": "75 mg capsules\n                  \n                  White to off White color granular powder filled in Size \"4\" hard gelatin capsules with White Opaque body imprinted \"PGBN\" and light blue Opaque cap imprinted \"75\" with black ink available in:\n                  Storage and Handling\n                  Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).",
    "adverseReactions_original": "Pregabalin is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy \n                        [see Warnings and Precautions (5.2)]."
}